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Abstract
Pain is the most feared symptom associated with cancer and the most
prominent symptom reported in cancer patients. Pain management has
been extremely difficult to achieve, despite the availability of a number of
pharmacological and nonpharmacological approaches, including the use of
analgesics, biological therapy, targeted cancer therapies and tumour shrink-
ing paradigms such as chemotherapy and radiation. The correct use of the
analgesic ladder advised by World Health Organisation (WHO) can lead to
adequate long- term pain control in most patients with advanced cancer
disease.
Opioids are the primary and most effective treatment for cancer-induced
pain remaining the cornerstone of pharmagological treatment. Adequate
analgesic treatment is not only intended to reduce pain, above all it is aimed
to increase the quality of life for cancer patients.
INTRODUCTION
World Health Organisation (WHO) in year 2008. reported that thepatients at the time of cancer diagnosis suffered moderate to se-
vere pain in 30–40% off patients, while 60–100% off patients with ad-
vanced disease suffered severe pain.
Pain in patients with cancer can be caused by the cancer itself, asso-
ciated with tumor compression, caused by chemotherapy or radiation
and by surgical treatment. Pain caused by cancer is mostly nociceptive
pain and can occur as somatic or visceral. Neuropathic pain is a result
of tumour infiltration or compression of nerves (eg. muscle spasms,
lymphedema, constipation, bed sores). Pain caused by chemotherapy is
a result of development of polyneuropathy. Post radiation damaging
leads to radiation plexopathy (brachial, lumbar) and radiation myelo-
pathy. Neuropathy as a result of surgical treatment occurs predomi-
nantly after particular surgical procedures and the most common is
postthoracotomy pain, postmastektomy pain, pain after radical neck
dissection or post amputation pain (1, 2, 3).
Patients with malignant diseases represent a very specific group of
patients due to increase in pain in these patients is often associated with
the progression of disease and stress.
Furthermore, cancer pain causes variety of symptoms known as
»cytokine-induced sickness behaviour«. This condition includes pain,
sleep disturbance, cognitive impairment leading to depression, leth-
argy, anorexia, chronic fatigue. It is believed that the trigger for the de-
velopment of behavioural problems is primarily due to continous re-
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Education/new procedures
Since the cancer pain is associated with a variety of
other sings and symptoms strongly influencing the ev-
eryday living, the efficient treatment of cancer pain is
crucial for quality of life.
A basic recommendation
A basic recommendation for the treatment of cancer
pain has been proposed in 1986. by WHO and it consists
of the three step analgesic ladder (5). First step include
the treatment of mild pain and the application of non-
opioids drug (paracetamol, NSAIDs, COX-2 inhibitors,
metamizole) is recommended. Second step implies the
treatment of moderate pain by weak opioids (Zaldiar,
tramadole, codeine). Third step recommends strong opio-
ids (morphine, fentanyl, methadone, oxycodone) for the
treatment of severe pain (Figure 1.).
Since the implementation of this scale in clinical
practice for cancer pain relief has shown to bee too slow
and insufficient, last few years it has been modified. Can-
cer pain is usually very intensive, and recently it has been
proposed that the initial application of the strong opioids
should be recommended instead of gradual augmenta-
tion from nonopioid drugs and weak opioids. This type
of pain management is called analgesic lift.
Selection of analgesic for cancer pain relief depends
on pain intensity, pain duration, ethiology of pain, degree
of patients sensitivity to pain, tolerability of analgesics,
previous use of analgesics, and the possibilities of getting
used to. To achieve adequate pain relief by suppressing
different pain pathways usually is recommended the use
off two or more analgesics which have a synergistic effect
in order to minimize adverse effects compared with the
use of high doses of just one drug. The dose and effect of
analgesics is individual. Recent research on human mod-
els indicate that the analgesic response is written in the
individual genetic map explaining the fact that the anal-
gesic dose insufficient for one patient in another patient
can cause symptoms of over dosage (2, 6).
Opioid analgetics
Delay prescription of opioid analgetics for cancer pa-
tients is very common due to fear off their effect to cause
the addiction (physical and psychological), development
of tolerance, multiple side effects and most of all because
there is lack of knowledge including medical stuff.
Central effects of opioids
Central effects of opioids include analgesia, sedation,
euphoria or dysphoria, respiratory depression, antitusic
effect, emetic effect, miosis and development of tolerance.
Peripheral effects of opioids
Peripheral effects of opioids include slowing gastric
emptying (pyloric constriction), slowing gut motility and
increased intestinal muscle tone, contraction of the
sphincter of the gall bladder, and increased muscle tone
of the bladder, decrease in vascular tone and release of
histamine (7, 8).
Side effects of opioids
Common side effects of opioids are constipation, se-
dation, nausea and vomiting, delirium, myoclonus, pru-
ritus and respiratory depression (9).
The most common and simplest method of adminis-
tration of analgesics for the treatment of malignant pain
is an oral route. Analgesics must be taken »on hour«, »on
demand« is allowed only for breakthrough pain. Break-
through pain has been defined as a transitory increase in
pain intensity over a baseline pain intensity in patient re-
ceiving in time administered analgesic treatment. The
use of a short half-life opioid, such as immediate-release
morphine is suggested for breakthrough pain.
Only if the oral route is absolutely impossible, other
alternative routes are recommended.
Intravenous route is indicated in patients with ad-
vanced tumours of the oesophagus, neck, gut obstruc-
tion, etc., which leads to an inability to swallow or with
recurrent nausea and vomiting which prevents the ab-
sorption of drugs. Intravenous use of opioids can be
achieved by rapid titration, but patients must be continu-
ously monitored and it usually requires hospitalization.
Intravenous analgesia can be used in household condi-
tions, as continuous infusion controlled by the patient
(Patient Controlled Analgesia PCA).
Subcutaneous administration of opioids could be
recommended when the oral application can not be ap-
plied. When subcutaneous infusion is applied, the loca-
tion of drug application should be changed frequently.
Intramuscular injections are not recommended, be-
cause they are painful, the absorption of analgesics is un-
predictable especially in dehydrated and hypotensive pa-
tients.
Rectal administration of opioids is an alternative
route when the patient can not take medicine orally be-
cause of nausea and vomiting or intestinal obstruction.
Most of analgesics intended for oral use can be applied
rectal (e.g. morphine tablets) (10).
Epidural application of analgesics is intended pri-
marily for postoperative analgesia because it provides an-
algesia at the origin of painful stimuli, which enables
rapid patient mobilization, reduces stress response, en-
courage faster gut motility and reduces the intensity and
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frequency of side effects. Epidural analgesia is achieved
primarily by opioid analgesics which are commonly com-
bined with local anaesthetics that have proinflamatory
effect. There are a number of other medications that can
be applied as additives such as clonidine, ketamine, epi-
nephrine, neostigmine, naloxon, to extend and improve
epidural analgesia and diminish side effects (11, 12).
Transdermal drug administration has brought a revo-
lution in the treatment of chronic pain because drug re-
lease rate is controlled and constant plasma concentra-
tion of the drug is maintained over a long period. When
the anagestic is applied transdermally the patients are
not constantly focused on their pain and its treatment.
Transdermal preparations contributed significantly to the
quality of treatment of cancer pain particularly in pa-
tients who have difficulty swallowing.
The most recent application of analgesics for cancer
pain are: oral tranmucosal route, sublingual route, intra-
nasal and inhalation route (10).
Adjuvant drugs
Adjuvant drugs cure side effects of analgesics (eg.
antiemetic and laxatives), enhance pain relief usually
caused by nerve compression (eg. corticosteroids), cure
comparative psychological disorders such as insomnia,
anxiety and depression (sedative, anxiolytics and antide-
pressants) (14).
Biological therapy
Biological therapy is a type of treatment that works to
enhance immune system to fight against cancer cells or
to control side effects of other cancer treatments like che-
motherapy. Biological therapy keeps cancer from spread-
ing to other parts of patients body, stop or slow the
growth of cancer cells and make it easier for immune sys-
tem to destroy, or get rid of cancer cells (15).
Cancer vaccines
Cancer vaccines are a form of biological therapy.
While other vaccines are given before the disease occurs,
cancer vaccines are given after the cancer appears. Can-
cer vaccines may help the body to fight against the cancer
and can be effective to prevent cancer reoccurrence (16).
Targeted cancer therapies
Targeted cancer therapies are drugs or other sub-
stances that block the growth and spread of cancer by in-
terfering with specific molecules involved in tumor growth
and progression. These substances are usually called
»molecular targets«, »molecularly targeted drugs«, »mo-
lecularly targeted therapies«, or other similar names. By
focusing on molecular and cellular changes that are spe-
cific to each cancer, targeted cancer therapies may be
more effective than other types of treatment, including
and , and less harmful to normal cells (17). Targeted can-
cer therapies interfere with cancer cell division (prolifera-
tion) and spread in different ways. Many of these thera-
pies focus on that are involved in cell signaling path-
ways, which form a complex communication system that
governs basic cellular functions and activities, such as
cell division, cell movement, how a cell responds to spe-
cific external stimuli, and even cell death. By blocking
signals that tell cancer cells to grow and divide uncon-
trollably, targeted cancer therapies can help stop cancer
progression and may induce cancer cell death through a
process known as . Other targeted therapies can cause
cancer cell death directly, by specifically inducing apop-
tosis, or indirectly, by stimulating the immune system to
recognize and destroy cancer cells and/or by delivering
toxic substances to them (17).
No pharmacological interventions
No pharmacological interventions used in cancer pain
management are: neuromodulation techniques (TENS,
SCS, DBS, acupuncture), therapeutic nerve blocks, phy-
sical and occupational therapy, psychological and behav-
ioural techniques and neurodestructive techniques (18).
CONCLUSION
Cancer pain is chronic pain that is the result of a com-
plex pathophysiological events between the three major
systems: nervous, endocrine and immune system. Un-
derstanding the network of complex interactions bet-
ween the nervous, immune and endocrine system will
contribute to the targeted treatment of patients with can-
cer pain. Additionally, patients with cancer have reduced
immune system due to numerous factors, particularly
the pain. Immunosuppression contributes to increased
tendency of developing infections and promoting tu-
mour growth.
Treatment of cancer pain is multimodal. Although
opioid pharmacotherapy can be considered the corner-
stone in the treatment of malignant pain, other pharma-
cological and non-pharmacological methods should be
considered as very important part of pain treatment. Ad-
ditionally, psychological support to the patients and their
family should be mandatory.
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